tiprankstipranks
Trending News
More News >
Elekta AB (SE:EKTA.B)
:EKTA.B
Advertisement

Elekta AB (EKTA.B) AI Stock Analysis

Compare
3 Followers

Top Page

SE:EKTA.B

Elekta AB

(LSE:EKTA.B)

Rating:64Neutral
Price Target:
kr53.00
▲(8.30%Upside)
Elekta AB's overall stock score reflects a mix of stable financial performance and high valuation concerns. The financial performance is relatively strong but challenged by profitability and leverage issues. Technical analysis indicates a neutral to slightly bearish outlook, while valuation metrics suggest the stock may be overvalued, tempered by an attractive dividend yield.

Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)

Elekta AB Business Overview & Revenue Model

Company DescriptionElekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyElekta AB generates revenue primarily through the sale of its advanced medical equipment and associated software solutions to healthcare institutions globally. The company's key revenue streams include the sale of linear accelerators for radiation therapy, Leksell Gamma Knife systems for radiosurgery, and brachytherapy solutions. In addition to equipment sales, Elekta earns money from software licenses, service contracts, training, and support services that ensure the effective use of their technologies. Significant partnerships with hospitals, research institutions, and strategic collaborations also play a role in expanding Elekta's reach and enhancing its product offerings, contributing to its earnings.

Elekta AB Financial Statement Overview

Summary
Elekta AB's financial performance is stable but challenged. The company maintains a strong equity base and efficient cash conversion, yet faces profitability and leverage challenges. Revenue inconsistencies and declining profit margins highlight the need for improved operational efficiency and risk management.
Income Statement
70
Positive
Elekta AB's income statement shows a mixed performance. The company has experienced fluctuations in revenue over the years, with a decline in 2025 compared to 2024. The gross profit margin is relatively stable, but net profit margins have decreased significantly in 2025 due to a lower net income. EBIT and EBITDA margins have also shown a downward trend, indicating reduced operational efficiency.
Balance Sheet
75
Positive
The balance sheet reveals a stable financial position. Elekta AB maintains a healthy equity ratio, suggesting a strong equity base relative to its total assets. However, the debt-to-equity ratio is relatively high, indicating potential leverage risk. Return on equity has declined, reflecting reduced profitability in relation to shareholder equity.
Cash Flow
65
Positive
Cash flow analysis indicates some concerns. Operating cash flow has increased over the years, but the free cash flow growth rate is inconsistent. The operating cash flow to net income ratio is relatively strong, suggesting efficient earnings conversion to cash. However, free cash flow to net income ratio indicates some challenges in maintaining positive free cash flow relative to net income.
BreakdownJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue18.02B18.12B16.87B14.55B13.76B
Gross Profit6.75B6.78B6.35B5.44B5.61B
EBITDA2.19B3.29B2.57B2.74B3.13B
Net Income237.00M1.30B943.00M1.15B1.25B
Balance Sheet
Total Assets28.98B31.41B29.61B26.30B24.84B
Cash, Cash Equivalents and Short-Term Investments2.96B2.78B3.27B3.07B4.40B
Total Debt7.57B7.25B6.67B5.70B6.24B
Total Liabilities20.13B20.63B19.88B17.39B16.65B
Stockholders Equity8.80B10.77B9.73B8.91B8.20B
Cash Flow
Free Cash Flow1.06B817.00M400.00M450.00M1.71B
Operating Cash Flow2.63B2.46B1.96B1.86B2.55B
Investing Cash Flow-1.67B-1.92B-1.61B-1.65B-613.00M
Financing Cash Flow-607.00M-1.10B-129.00M-1.73B-3.60B

Elekta AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price48.94
Price Trends
50DMA
49.39
Positive
100DMA
50.86
Negative
200DMA
56.97
Negative
Market Momentum
MACD
-0.10
Negative
RSI
57.56
Neutral
STOCH
75.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Positive. The current price of 48.94 is above the 20-day moving average (MA) of 48.63, below the 50-day MA of 49.39, and below the 200-day MA of 56.97, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 75.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EKTA.B.

Elekta AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
kr19.03B80.282.43%4.82%-0.57%-81.80%
52
Neutral
$7.65B0.16-63.14%2.08%16.38%0.82%
€108.43M45.507.87%
€80.15M-19.17%
€35.30M-88.97%
€6.01M
€146.43M-5.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:EKTA.B
Elekta AB
48.94
-16.57
-25.30%
DE:24C
C-Rad AB Class B
3.10
-0.68
-17.99%
DE:6Y1
Integrum AB Class B
3.70
-0.50
-11.90%
DE:7AC
Acarix AB
0.03
-0.01
-25.00%
DE:7820
Scandinavian Real Heart AB
1.13
-1.13
-50.00%
DE:7D2A
Sedana Medical AB
1.37
-0.60
-30.46%

Elekta AB Corporate Events

Elekta’s Gamma Knife System Gains FDA Clearance for Epilepsy Treatment
Jul 23, 2025

Elekta has received U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat refractory, drug-resistant mesial temporal lobe epilepsy (MTLE) in adults. This clearance allows U.S. providers to offer a non-invasive, precision treatment option for epilepsy, potentially improving patient outcomes and optimizing resource utilization. The Gamma Knife system, originally developed for functional indications like epilepsy, has been a non-invasive alternative for nearly two million patients globally, sparing healthy brain tissue and critical structures.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta AB’s 2024/25 Annual Report: Advancing Cancer Care
Jul 4, 2025

Elekta AB’s annual report for 2024/25 highlights its commitment to advancing cancer care through innovation and collaboration. The report emphasizes the company’s dedication to setting new standards in treatment, reflecting its strategic milestones and sustainability efforts. This announcement underscores Elekta’s role in the healthcare sector, aiming to make a significant impact on cancer treatment and patient lives.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Proposes Board Reelection and New Director Appointment
Jun 12, 2025

Elekta’s Nomination Committee has proposed the reelection of several board members and the election of Jan De Witte as a new director for the upcoming term. Jan De Witte brings extensive leadership experience from the global technology and life science industries, which could enhance Elekta’s strategic direction and industry positioning.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Unveils Strategic Growth Plans and Product Innovations at Investor Update
Jun 10, 2025

Elekta’s Investor Update in Stockholm showcased its innovative portfolio and strategic growth plans, including restoring gross margin and achieving a 14% EBIT margin. The company highlighted its proactive order review, resulting in a SEK 4.9 billion cancellation, and discussed the positive market reception of its latest products, emphasizing the importance of adaptive radiation therapy in improving clinical outcomes.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Appoints Jakob Just-Bomholt as New CEO
Jun 9, 2025

Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025. With a strong background in international leadership and innovation, Just-Bomholt is expected to drive Elekta’s growth and global expansion, enhancing its market position and delivering value to stakeholders, including shareholders, customers, and cancer patients worldwide.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Strengthens Cancer Treatment in Croatia with Strategic Acquisition
Jun 5, 2025

Elekta has acquired assets from its distributor in Croatia, a strategic move to enhance its market position and improve cancer treatment capabilities in the region. This acquisition will allow Elekta to establish a direct presence in Croatia, including an office in Zagreb and the hiring of additional staff, which is expected to positively impact patient care by providing access to advanced cancer treatment technologies. The Croatian Ministry of Health’s order for Elekta’s equipment will address the country’s shortage of radiotherapy units, aligning with Croatia’s National Cancer Plan.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK63.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta AB Reports Strong Q4 Performance with Best Gross Margin in Five Years
May 28, 2025

Elekta AB reported a 6% increase in net sales for the fourth quarter of 2024/25 at constant exchange rates, driven by strong performance in Europe and APAC, and a 3% increase in reported sales. The company achieved its best fourth-quarter gross margin in five years at 40.3%, supported by price increases, product launches, and a solid performance of its Elekta Evo linear accelerator and Elekta ONE software suite. Despite a non-cash impairment of SEK 1,064 M due to discontinued R&D projects, Elekta maintained a strong book-to-bill ratio and improved cash flow. The company expects continued sales growth and margin improvements, aiming to reach pre-pandemic levels, while its products have received positive feedback from healthcare providers.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta to Present Fiscal Year 2024/25 Developments
May 13, 2025

Elekta has announced a presentation for its fiscal year 2024/25, scheduled for May 28, where the company’s Acting President and CEO, Jonas Bolander, along with CFO Tobias Hägglöv, will discuss the company’s development. The event, which includes a live webcast and Q&A session, reflects Elekta’s commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025